VANCOUVER, BC, July 29, 2014 (GLOBE NEWSWIRE) -- via PRWEB - According to a new report series by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the Global Cardiac Surgery Devices Market will grow to over $8 billion by 2018. This growth will be fueled by extensive technological advancement, particularly in the transcatheter heart valve market, which is comprised of both the transcatheter heart valve implantation (THVI) and the transcatheter mitral valve repair (TMVR) segments.
There are many risks associated with performing traditional open cardiac surgery such as neurological damage and strokes after procedures. Neurological damage is more common when an On-Pump Coronary Artery Bypass procedure is performed; many patients suffer from post-perfusion syndrome, which is a combination of neurological conditions that can affect patients after surgery. These symptoms can be temporary or permanent. "The introduction of transcatheter heart valve repair and implantation has seen tremendous growth," says Dr. Zamanian, CEO of iData. "Such procedures require less recovery time and are less strenuous on the patient than open cardiac surgery."
Other key findings from the Global Transcatheter Heart Valve Devices Market:
Transcatheter Mitral Valve Repair (TMVR): Mitral regurgitation is the second most common heart valve disease in the world. TMVR is a preferred treatment option for mitral regurgitation for patients with significant, symptomatic, degenerative mitral regurgitation that are at prohibitive risk for traditional open surgery. The three key players and products within this market includes Abbott Vascular's MitraClip™, the world's first TMVR device; Cardiac Dimensions's CARILLON® Mitral Contour System and Mitralign's own signature device that is currently in clinical trial outside of the United States.
Transcatheter heart valve implantation (THVI): The total THVI device market comprises the transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve implantation (TMVI) devices. As of 2013, there were only TAVI products approved for sale in Europe and the U.S.
Main competitors and their associated devices include: Edwards LifeSciences's SAPIEN, Medtronic's CoreValve®, Boston Scientific's Lotus™ Valve System and Direct Flow Medical's Portico™ Transcatheter Aortic Valve Implantation System.
Transcatheter Mitral Valve Implantation (TMVI): Multiple competitors are investing in research and development in order to introduce a TMVI device into the market. One of the companies leading this market is CardiAQ Valve Technologies, their TMVI device is designed to address the challenges of the mitral position.
For More Information
The global series "Markets for Cardiac Surgery Devices" covers the U.S., Asia and 15 countries in Europe. The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market share and analysis of major plays' success strategies in each market and segment.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopaedics, Cardiovascular, Ophthalmic, Endoscopy, Gynecology, Urology and more.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/07/prweb12053824.htm